Core Viewpoint - The company reported a significant increase in revenue but a substantial decline in net profit during the reporting period [1] Financial Performance - The company achieved operating revenue of 302.40 million yuan, representing a year-on-year growth of 29.33% [1] - The net profit attributable to shareholders was -11.15 million yuan, a decrease of 117.88% compared to the same period last year [1] Product Sales - Revenue from self-produced products increased by 44.71% year-on-year, with a gross margin improvement of 3.78% [1] - Revenue from non-self-produced products decreased by 36.74% year-on-year, with a gross margin decline of 1.40% [1] Financial Costs - The interest on convertible bonds included in financial expenses amounted to 14.68 million yuan, which had a certain impact on net profit [1]
共同药业(300966.SZ)：上半年净亏损1115.25万元